We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+2%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$339M
AUM Growth
+$36.2M
Cap. Flow
+$31.5M
Cap. Flow %
9.29%
Top 10 Hldgs %
40.44%
Holding
118
New
22
Increased
42
Reduced
29
Closed
25

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$9.37M
2
LH icon
Labcorp
LH
+$7.04M
3
JNJ icon
Johnson & Johnson
JNJ
+$6.49M
4
BDX icon
Becton Dickinson
BDX
+$5.83M
5
UHS icon
Universal Health Services
UHS
+$5.72M

Top Sells

Rank Stock Value
1
AMSG
Amsurg Corp
AMSG
+$5.97M
2
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$5.94M
3
HOLX
Hologic
HOLX
+$5.76M
4
CYH icon
Community Health Systems
CYH
+$4.33M
5
CAH icon
Cardinal Health
CAH
+$4.22M

Sector Composition

Rank Sector Weight
1 Healthcare 89.84%
2 Financials 0.85%
3 Technology 0.78%
4 Real Estate 0.25%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALR
26
DELISTED
AlerisLife Inc
ALR
$4.29M 1.27%
89,335
+81,225
+1,002% +$3.69M
ISRG icon
27
Intuitive Surgical
ISRG
$127B
$4.21M 1.24%
78,300
+9,900
+14% +$554K
ESRX
28
DELISTED
Express Scripts Holding Company
ESRX
$4.15M 1.23%
46,700
-22,500
-33% -$1.97M
NVS icon
29
Novartis
NVS
$297B
$4.15M 1.22%
47,095
-21,651
-31% -$1.99M
VRTX icon
30
Vertex Pharmaceuticals
VRTX
$121B
$4.06M 1.2%
32,900
+18,500
+128% +$2.33M
BAX icon
31
Baxter International
BAX
$13.5B
$3.64M 1.08%
95,916
-10,862
-10% -$406K
ELOS
32
DELISTED
Syneron Medical Ltd
ELOS
$3.5M 1.03%
329,914
+231,114
+234% +$2.71M
QGENF
33
DELISTED
QIAGEN NV
QGENF
$3.21M 0.95%
+129,300
New +$3.21M
KTWO
34
DELISTED
K2M Group Holdings, Inc
KTWO
$2.91M 0.86%
121,133
-41,989
-26% -$1M
AET
35
DELISTED
Aetna Inc
AET
$2.87M 0.85%
22,550
-3,400
-13% -$388K
ZBH icon
36
Zimmer Biomet
ZBH
$18.2B
$2.72M 0.8%
+25,647
New +$2.84M
NSTG
37
DELISTED
NanoString Technologies, Inc.
NSTG
$2.71M 0.8%
175,961
-187,717
-52% -$2.51M
ZVRA icon
38
Zevra Therapeutics
ZVRA
$562M
$2.68M 0.79%
+9,106
New +$1.99M
KND
39
DELISTED
Kindred Healthcare
KND
$2.67M 0.79%
131,500
+59,100
+82% +$1.35M
CSLT
40
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$2.65M 0.78%
326,223
+66,923
+26% +$558K
BSX icon
41
Boston Scientific
BSX
$69.5B
$2.57M 0.76%
145,100
-98,100
-40% -$1.75M
A icon
42
Agilent Technologies
A
$39.1B
$2.46M 0.72%
63,665
-5,100
-7% -$212K
CELG
43
DELISTED
Celgene Corp
CELG
$2.37M 0.7%
20,460
-9,500
-32% -$1.09M
AMPH icon
44
Amphastar Pharmaceuticals
AMPH
$879M
$2.35M 0.69%
133,559
-18,600
-12% -$290K
BDSI
45
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.33M 0.69%
293,100
+270,400
+1,191% +$2.32M
VTRS icon
46
Viatris
VTRS
$20.4B
$2.18M 0.64%
32,100
+22,500
+234% +$1.59M
HUM icon
47
Humana
HUM
$43.7B
$2.12M 0.63%
11,098
-1,300
-10% -$241K
PARN
48
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$2.02M 0.59%
407,143
+119,980
+42% +$529K
CI icon
49
Cigna
CI
$73.7B
$1.98M 0.58%
12,200
-1,400
-10% -$193K
JAZZ icon
50
Jazz Pharmaceuticals
JAZZ
$15.9B
$1.94M 0.57%
11,000
+300
+3% +$53.9K
1
2
3 4 5

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Endurant Capital Management held 118 positions worth $339M, up 12% from $303M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Endurant Capital Management deployed $31.5M of net new capital in Q2 2015, opening 22 new positions and adding to 42 existing holdings. Its largest new stake was EndoChoice Holdings, Inc.: 328,501 shares worth $5.37M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 88% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Amsurg Corp, an estimated $5.97M trimmed.

  • Endurant Capital Management's largest Q2 2015 buy was EndoChoice Holdings, Inc.: 328,501 shares worth $5.37M.
  • Endurant Capital Management added most to Merck in Q2 2015, an estimated $9.37M increase.
  • Endurant Capital Management's biggest Q2 2015 reduction was Amsurg Corp, cutting an estimated $5.97M.
  • Endurant Capital Management fully exited AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q2 2015, selling an estimated $5.94M.
  • Endurant Capital Management's ten largest holdings make up 40% of its $339M portfolio in Q2 2015.
  • Endurant Capital Management opened 22 new positions and closed 25 in Q2 2015.
  • Endurant Capital Management's portfolio value rose 12% quarter-over-quarter to $339M.

Based on Endurant Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.